Literature DB >> 3396191

Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses.

P G Holt1, J Vines, D Britten.   

Abstract

Sublingual administration of a protein allergen to immunologically naïve rats suppressed subsequent allergen-specific IgE responses. Susceptibility to this form of immunotherapy was genetically determined, with some inbred rat strains displaying immunological tolerance in the IgE antibody class alone, whilst others developed concomitant suppression of IgG. Parallel gastric intubation experiments established that the development of tolerance by sublingual allergen administration proceeded independently of events occurring in the gut resulting from swallowing the allergen. These results are consistent with clinical reports which suggest that the oral mucosa is a potentially useful site for therapeutic modulation of allergic reactivity, and indicate that appropriate animal models can be developed to probe this important question. However, further research is required to determine the relevance of these findings to current sublingual desensitization practices.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396191     DOI: 10.1111/j.1365-2222.1988.tb02864.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  3 in total

1.  The engagement of oral-associated lymphoid tissues during oral versus gastric antigen administration.

Authors:  Maria Bankvall; Anna-Karin Östberg; Mats Jontell; Agnes Wold; Sofia Östman
Journal:  Immunology       Date:  2016-09       Impact factor: 7.397

2.  Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair.

Authors:  E J Van Wilsem; I M Van Hoogstraten; J Brevé; R J Scheper; G Kraal
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

3.  Reduced frequency of nickel allergy upon oral nickel contact at an early age.

Authors:  I M Van Hoogstraten; K E Andersen; B M Von Blomberg; D Boden; D P Bruynzeel; D Burrows; J G Camarasa; A Dooms-Goossens; G Kraal; A Lahti
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.